Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company’s lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The company’s platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.
Location: United States, Texas
Employees: 11-50
Total raised: $79M
Founded date: 2011
Investors 5
| Date | Name | Website |
| 14.03.2024 | Linden Cap... | lindenllc.... |
| - | HealthQues... | healthques... |
| 25.12.2021 | Bessemer V... | bvp.com |
| - | Frazier Li... | frazierls.... |
| - | Linden Cap... | linden.com... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 27.02.2020 | - | $10M | - |
| 17.06.2016 | - | $49M | - |
| 22.07.2013 | Series B | $10M | - |
| 17.04.2012 | Series A | $10M | - |
Mentions in press and media 11
| Date | Title | Description |
| 13.05.2024 | Alcresta Therapeutics Announces Commercial Availability of Next-Generation RELiZORB® (iMMOBILIZED LIPASE) Cartridge | Commercial availability of RELiZORB marks important step to supporting more tube-fed patients including those living with short bowel syndrome and other rare diseases. WALTHAM, Mass., May 13, 2024 /PRNewswire/ -- Alcresta Therapeutics, Inc.... |
| 12.03.2024 | Linden Capital Partners Acquires Alcresta Therapeutics, Inc. | CHICAGO and WALTHAM, Mass., March 12, 2024 /PRNewswire/ -- Linden Capital Partners ("Linden"), a Chicago-based private equity firm focused exclusively on the healthcare industry, announced today the completion of its acquisition o... |
| 12.03.2024 | Linden Invests in Alcresta Therapeutics | Chicago, IL (March 12, 2024) – Linden Capital Partners (“Linden”), a Chicago-based healthcare private equity firm, announced today the completion of its acquisition of Alcresta Therapeutics, Inc. (“Alcresta” or “the Company”), a leader in c... |
| 01.12.2017 | CVS and Amazon battle to own the health care consumer | Two reports have set the healthcare community abuzz this week. The first uncovered that CVS is considering buying health insurance giant Aetna. The second revealed that Amazon has obtained pharmacy licenses in multiple states. (A closer loo... |
| 17.06.2016 | UPDATED: Alcresta raises $49M for digestive enzyme launch | Alcresta has raised $49.4 million in a Series C financing to support the launch of its novel digestive enzyme cartridge Relizorb. Up first, it's aiming for the sub-set of cystic fibrosis patients who rely upon a feeding tube for nutrition. ... |
| 22.07.2013 | Alcresta Secures $10M Series B | NEWTON, MA, Leading medical nutrition company developing innovative enzyme-based products for adults, infants, and individuals battling acute conditions or chronic diseases, today announced that it has secured $10 million in Series B fina... |
| 22.07.2013 | Alcresta Secures $10 Million Series B Financing, Prepares for 2014 Commercial Launch of Novel Point-of-Care Nutritional Products | Alcresta Secures $10 Million Series B Financing, Prepares for 2014 Commercial Launch of Novel Point-of-Care Nutritional Products Robert Gallotto Promoted to President as Company Completes Transition to Commercial Stage and Prepares for Cont... |
| 22.07.2013 | Alcresta Raises $10M in Series B Financing | Alcresta, a Newton, MA-based medical nutrition company developing innovative enzyme-based products for adults, infants, and individuals battling acute conditions or chronic diseases, raised $10m in Series B financing. The round was led by e... |
| 17.04.2012 | Alcresta Secures $10M Series A | NEWTON, MA, Company developing innovative enzyme-based nutritional products for infants, adults and patients battling acute or chronic conditions, today announced a $10 million Series A. >> Click here for more funding data on Alcre... |
| 17.04.2012 | Alcresta Raises $10M in Series A Financing | Alcresta, a Newton, Mass.-based company developing innovative enzyme-based nutritional products for infants, adults and patients battling acute or chronic conditions, has raised $10m in Series A venture capital financing. The round was led ... |
Show more